ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122

Cong, Xiaonan; He, Yundong; Wu, Haigang; Wang, Dingxiang; Liu, Yongrui; Shao, Ting; Liu, Mingyao; Yi, Zhengfang; Zheng, Jianghua; Peng, Shihong*; Ding, Tao*南方医科大学; 上海大学; 上海交通大学; 6
Frontiers in Oncology2021-6-3DOI: 10.3389/fonc.2021.650919
4被引7阅读
引用收藏
分享

摘要

Prostate cancer (PCa) is a common aggressive disease worldwide which usually progresses into incurable castration-resistant prostate cancer (CRPC) in most cases after 18-24 months treatment. Androgen receptor (AR) has been considered as a crucial factor involved in CRPC and the study of AR as a potential therapeutic target in CRPC may be helpful in disease control and life-cycle management. In this study, we identified a potent small molecule compound, HG122, that suppressed CRPC cells proliferation and metastasis, and inhibited tumor growth both in subcutaneous and orthotopic tumor model. In addition, HG122 reduced the mRNA expression of PSA and TMPRSS2 which are target genes of AR, resulting in cell growth inhibition and metastasis suppression of CRPC, without affecting the expression of AR mRNA level. Mechanically, HG122 promoted AR protein degradation through the proteasome pathway impairing the AR signaling pathway. In conclusion, HG122 overcomes enzalutamide (ENZ) resistance in CRPC both in vitro and in vivo, thus suggesting HG122 is a potential candidate for the clinical prevention and treatment of CRPC.

学科与关键词

关键词
HG122castration-resistant prostate cancerandrogen receptorcancer treatmentmolecular compound
相关
加载中…
  • Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
    Luo, Mayao; Zhang, Yifan; Xu, Zhuofan; Wu, Chenwei; Ye, Yuedian; Liu, Rui*; Lv, Shidong*; Wei, Qiang*Cell Death Discovery, 2022, 8(1): 471.被引 1
  • IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
    Zhang, Yifan; Liao, Yuanpeng; Luo, Mayao; Ye, Yuedian; Xu, Zhuofan; Hou, Wenli; Liu, Ruiyu; Zhai, Qiliang; Lv, Shidong*; Wei, Qiang*PROSTATE, 2023, 83(15): 1446-1457.
  • Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glance
    Jian, Jingang; Wang, Xin'an; Zhang, Jun; Zhou, Chenchao; Hou, Xiaorui; Huang, Yuhua; Hou, Jianquan*; Lin, Yuxin*; Wei, Xuedong*Frontiers in Endocrinology, 2024, 15: 1360430.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2021-06-03
卷期
第 11 卷
页码
650919
DOI
10.3389/fonc.2021.650919
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
National Key R&D Program of China [2018YFA0507001]; National Natural Science Foundation of China [81830083, 82073310, 81773204, 81802970]; Innovation program of Shanghai municipal education commission [2017-01-07-00-05-E00011]; Fundamental Research Funds for the Central Universities; China Postdoctoral Science Foundation [2018M632065]; Science and Technology Commission of Shanghai Municipality [11DZ2260300, 20JC1417900]; Shenzhen Municipal Government of China [KQTD20170810160226082]; Science and Technology Commission Fund of Shanghai Fengxian District [20160907]; ECNU Construction Fund of Innovation and Entrepreneurship Laboratory [44400-20201-532300/021]; ECNU Public Platform for innovation [011]

作者

  • C

    Cong, Xiaonan (第一作者)

  • H

    He, Yundong

查看全部 11 位作者收起作者
  • W

    Wu, Haigang

  • W

    Wang, Dingxiang

  • L

    Liu, Yongrui

  • S

    Shao, Ting

  • L

    Liu, Mingyao

  • Y

    Yi, Zhengfang

  • Z

    Zheng, Jianghua

    shanghai univ

  • P

    Peng, Shihong (通讯)

  • D

    Ding, Tao (通讯)

    southern med univ · 6 · shanghai jiao tong univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417